GBT Announces New Employment Inducement Grants
April 03 2018 - 4:05PM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today
announced that on April 2, 2018, the compensation committee of the
Company’s board of directors granted one new employee an option to
purchase 750 shares of the Company’s common stock with a per share
exercise price of $44.20, the closing trading price on the grant
date, and a restricted stock unit award for 500 shares of the
Company’s common stock. All of the above-described awards were made
under the Company’s 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement
material to the employee entering into employment with the Company
in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted
pursuant to the terms of the Plan. The Company has reserved an
aggregate of 300,000 shares of its common stock (including the
shares underlying the stock options and restricted stock unit
awards described above) for issuance under the Plan, which was
approved by the Company’s Board of Directors in January 2017.
About Global Blood TherapeuticsGBT is a
clinical-stage biopharmaceutical company determined to discover,
develop and deliver innovative treatments that provide hope to
underserved patient communities. GBT is developing its lead product
candidate, voxelotor, as an oral, once-daily therapy for sickle
cell disease. To learn more, please visit www.gbt.com and follow
the company on Twitter @GBT_news.
Contact Information: Myesha Lacy
(investors)GBT650-351-4730investor@gbt.com
Julie Normart (media)W2O pure 415-946-1087media@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Oct 2023 to Oct 2024